You-Ri Kang

You-Ri Kang

Auto-generated profile, based on publicly available information

You-Ri Kang

Department of Neurology, Chonnam National University Hospital, Gwangju, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
SKSu-Hyun Kim
Su-Hyun Kim
JMJoo Min
Joo Min
SKSung-Min Kim
Sung-Min Kim
ELEun-Jae Lee
Eun-Jae Lee
YLYoung-Min Lim
Young-Min Lim
HKHo Jin Kim
Ho Jin Kim
Kim SH, et al. J Clin Neurol. 2025 Mar;21(2):131-136. https://doi.org/10.3988/jcn.2024.0485

28 April 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
YKYou-Ri Kang
You-Ri Kang
HJHyunjin Ju
Hyunjin Ju
KKKi Hoon Kim
Ki Hoon Kim
SCSeung Ho Choo
Seung Ho Choo
WJWoohee Ju
Woohee Ju
HKHo Jin Kim
Ho Jin Kim
Background: Research on the optimal duration of immunosuppressive therapy (IST) and the outcome upon its discontinuation in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains limited. Objective: To evaluate the outcomes following IST discontinuation in MOGAD. Methods: This multicenter retrospective study collected data from 333 MOGAD patients in Korea. Among 273 patients who received IST, 41 who discontinued IST were analyzed. Results: The median age at disease onset was 38.3 years (interquartile range (IQR), 27.6–53.1). Before IST withdrawal, 21 (51%) patients exhibited relapsing courses. Over a median follow-up of 23.5 months (IQR, 12.1–39.5) after discontinuation, 10 patients (24.4%) relapsed after a median of 8.2 months (IQR, 6.3–11.5). All relapses occurred in patients with a prior relapsing course (10/21, 47.6%); none with prior monophasic courses relapsed. Among 21 prior relapsing patients, relapse after discontinuation group had a shorter IST duration than non-relapse group (median, 9.4 vs 50.9 months, p = 0.036). None of the 41 patients had severe disability (Expanded Disability Status Scale (EDSS) score ⩾ 4.0 or Visual Functional System score ⩾ 5) at the last visit. Conclusion: IST discontinuation did not necessarily lead to relapse and could be considered with an individualized approach based on factors such as disease course and IST duration.

1 March 2026 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
YKYou-Ri Kang
You-Ri Kang
KKKi Hoon Kim
Ki Hoon Kim
JHJae-Won Hyun
Jae-Won Hyun
SKSu-Hyun Kim
Su-Hyun Kim
HKHo Jin Kim
Ho Jin Kim
Disability in neuromyelitis optica spectrum disorder (NMOSD) is traditionally considered relapse-driven, but recent studies have suggested possible subclinical progression. Whether this translates into clinically meaningful disability worsening remains unclear, and quantitative data on progression independent of relapse activity (PIRA) in NMOSD are limited. We investigated the frequency and clinical relevance of PIRA in a large cohort with long-term follow-up. We retrospectively analyzed 281 patients with AQP4-IgG-positive NMOSD with ≥2 years of follow-up. Significant Expanded Disability Status Scale (EDSS) worsening occurred following conventional thresholds, using a roving baseline. PIRA was defined as EDSS worsening without relapse between assessments, confirmed ≥6 months later, sustained, and not attributable to confounders. Relapse-associated worsening (RAW) was defined when the best EDSS score assessed ≥6 months after relapse still met the threshold. The mean follow-up duration was 11.3 ± 5.1 years, and the mean relapse-free duration was 8.3 ± 5.2 years. A total of 1,662 EDSS assessments were performed, with a median of 5 per patient (interquartile range, 4-7). Seven patients (2.5%) met PIRA criteria. Despite no treatment escalation, none worsened further. Among 194 patients with relapses, 70 (36.1%) experienced RAW. PIRA was rare, even with extended observation using a formal framework, reaffirming relapse as the principal driver of disability and supporting continued focus on relapse prevention.

27 December 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
SKSu-Hyun Kim
Su-Hyun Kim
YKYou-Ri Kang
You-Ri Kang
JCJieun Chung
Jieun Chung
MJMinji Joo
Minji Joo
RPRosah May Palermo Payumo
Rosah May Palermo Payumo
HKHo Jin Kim
Ho Jin Kim
Background: The kappa free light chain (KFLC) index is a quantitative marker of intrathecal immunoglobulin synthesis with diagnostic performance comparable to cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCBs). Its utility in Asian populations, where multiple sclerosis (MS) is less prevalent and mimics such as neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD) are common, remains underexplored. Objectives: We aimed to validate the KFLC index and determine optimal thresholds for MS diagnosis in a Korean cohort. Methods: We retrospectively analyzed 208 patients undergoing CSF evaluation, including 103 with MS and 105 with non-MS conditions (64 NMOSD, 14 MOGAD, 27 others). KFLC-related biomarkers were compared, and receiver operating characteristic analyses identified thresholds. Results: When comparing the MS group ( n = 103) with the non-MS group ( n = 105), the optimal KFLC index threshold was ⩾12.6, yielding sensitivity 84%, specificity 74%, and accuracy 79%. Combining KFLC index ⩾12.6 with OCB positivity increased specificity to 93%. Sex-specific thresholds (⩾22.8 for females, ⩾7.0 for males) improved performance, increasing male sensitivity and female specificity reaching 82%. Conclusion: The KFLC index is a reliable biomarker for MS diagnosis in Asian populations. Optimized and sex-specific thresholds may enhance diagnostic precision where MS mimics are relatively prevalent, consistent with diagnostic performance globally.

4 March 2022 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
YKYou-Ri Kang
You-Ri Kang
SLSo-Hyun Lee
So-Hyun Lee
NLNi-Hsuan Lin
Ni-Hsuan Lin
SLSeung-Jin Lee
Seung-Jin Lee
AYAi-Wen Yang
Ai-Wen Yang
TNTai-Seung Nam
Tai-Seung Nam

14 April 2026 in Neurology
Verified
Journal Article
Closed access
SKSu-Hyun Kim
Su-Hyun Kim
ELEun-Jae Lee
Eun-Jae Lee
YLYoung-Min Lim
Young-Min Lim
HKHyunjin Kim
Hyunjin Kim
JMJoo Min
Joo Min
HKHo Jin Kim
Ho Jin Kim
To provide the clinically validated, nationwide estimates of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Korea, and to describe their relative proportions. From January to March 2025, 47 referral hospitals participating in a nationwide hospital-based registry identified actively followed patients with MS, NMOSD, or MOGAD. Diagnoses followed international criteria, and antibody status was confirmed using validated CBAs. Actively followed patients had ≥1 outpatient visit in the prior 6 months. Centers provided demographics, treatments, and Expanded Disability Status Scale. Prevalence used national population data. A total of 4,196 patients were identified, 1,799 MS, 1,616 NMOSD, and 781 MOGAD (ratio 2.3:2.1:1). Mean age at onset was 33.4 ± 12.0 years for MS, 42.7 ± 14.7 for NMOSD, and 41.7 ± 17.8 for MOGAD, and the female-to-male ratios were 2.2:1 for MS, 5.1:1 for NMOSD (6.5:1 in aquaporin-4-IgG positive cases), and 1.5:1 for MOGAD. Crude prevalence estimates were 3.48, 3.13, and 1.51 per 100,000, respectively. This nationwide registry demonstrates a distinctive Korean CNS inflammatory demyelinating disease profile, with a relatively higher proportion of NMOSD and MOGAD reflecting the low prevalence of MS in East Asia.